Back

Title
  • en p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors
Creator
    • en Yamamoto, Mitsugu
    • en Nakano, Kiichiroh
    • en Jia, Shusheng
    • en Hatanaka, Kanako C.
    • en Takakuwa, Emi
    • en Matsuno, Yoshihiro
Accessrights open access
Rights
Subject
  • Other en Aromatase inhibitor
  • Other en breast cancer
  • Other en endocrine therapy
  • Other en p53
  • Other en prognosis
  • NDC 495
Description
  • Abstract en Aromatase inhibitors have played a central role in endocrine therapy for estrogen receptor (ER)-positive breast cancer in postmenopausal women. However, factors predictive of the efficacy of aromatase inhibitors, and prognostic factors, both for early and late recurrence in women treated with adjuvant aromatase inhibitors have not been identified. Whole genome analysis identified that a TP53 gene mutation exists in ER-positive breast cancers, although the frequency of TP53 gene mutation in luminal tumors is lower compared with basal-like or human epidermal growth factor receptor type 2 (HER2)-positive breast cancers. We examined expression of p53, as well as ER, progesterone receptor, HER2 and Ki-67 using immunohistochemistry in postmenopausal ER-positive breast cancer patients who were treated with aromatase inhibitors as adjuvant endocrine therapy. There were 53 (21%) tumors that contained 10% or more p53-positive cells. High p53 expression was positively correlated with tumor grade, HER2 score and Ki-67 expression. Significant association was observed between disease-free survival and high p53 expression in multivariate analysis (P<0.0001). Compared with women without recurrence, women with early recurrence had significantly higher p53 expression (P<0.0001), as did women with late recurrence (P=0.037). The present study demonstrates that p53 accumulation is a strong predictor of both early and late recurrence in ER-positive breast cancer patients treated with aromatase inhibitors as adjuvant endocrine therapy. TP53 gene alteration might be a key biological characteristic of ER-positive breast cancer.
Publisher en Wiley-blackwell
Date
    Issued2014-01
Language
  • eng
Resource Type journal article
Version Type VoR
Identifier HDL http://hdl.handle.net/2115/55116
Relation
  • isIdenticalTo DOI https://doi.org/10.1111/cas.12302
  • PMID 24118529
Journal
    • PISSN 1347-9032
    • EISSN 1349-7006
    • NCID AA11808050
      • en Cancer science
      • Volume Number105 Issue Number1 Page Start81 Page End88
File
Oaidate 2023-07-26